AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jun 20, 2018
33422_dirs_2018-06-20_421e19a1-622e-43df-acd4-5dbd9b02a650.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-14
Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-14 | Common Stock | S | 31860 | $7.99 | Disposed | 2769786 | Indirect |
| 2018-06-14 | Common Stock | S | 44525 | $8.48 | Disposed | 2725261 | Indirect |
| 2018-06-15 | Common Stock | S | 15475 | $8.47 | Disposed | 2709786 | Indirect |
| 2018-06-18 | Common Stock | S | 60000 | $9.06 | Disposed | 2649786 | Indirect |
Footnotes
F1: Common shares should pursuant to a trading plan pursuant to Rule 10b5-1. Price represents the gross sales price less commissions and brokerage fees.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.